BrainCo unveils a brain-to-robot developer platform at WAIC 2026 in Shanghai

By Inside BCI · July 18, 2026

At the BrainCo booth on the Shanghai floor of the World Artificial Intelligence Conference on Friday 17 July 2026, a person put on a lightweight EEG headband, sat down in front of a robotic arm, and thought about picking up a paper cup. The arm moved. It closed on the cup. The person did not press a button, speak a command, or twitch a muscle. On a second demonstration, the same headband directed the arm to lift an apple. The two grasps are the WAIC 2026 photograph that has gone out on Yahoo Finance, Morningstar, South China Morning Post, The Next Web, AI Weekly, 36 Kr, and every Chinese social media platform tracking the country’s biggest artificial intelligence trade show. They are the point of a product launch that BrainCo is calling its Brain-Controlled Robot AI Platform, and that the company describes, in its own press release, as the world’s first integrated brain-to-robot AI research-and-development platform.

The “world’s first” language is BrainCo’s own. Inside BCI is not repeating it as fact. A twenty-minute adversarial review turns up multiple prior demonstrations of EEG-driven robots: the MIT Media Lab’s Ddog project drove a Boston Dynamics Spot quadruped with a non-invasive EEG headband in 2024, published in Sensors; EMOTIV’s Cortex SDK and OpenBCI’s BrainFlow have offered commercial EEG-to-robot developer toolkits for over a decade; BrainCo itself has been selling a brain-controlled robotic prosthetic hand called BrainRobotics since 2020, with FDA clearance in 2022. What is genuinely new in Friday’s launch is not brain-controlled robotics in general. It is the packaging: a graphical, non-code development environment sold as a research platform, robot-agnostic across humanoid, arm, and quadruped form factors, aimed at China’s booming embodied-AI developer pool, and shipped as an integrated Neuro-Embodied-AI framework that pipes brain-intent decoding into AI action-planning and hands the resulting commands to third-party robot hardware.

What the platform actually is

The Brain-Controlled Robot AI Platform runs the same three-stage pipeline that every non-invasive brain-computer interface product runs. A wireless EEG headset captures scalp neural signals; an AI decoder translates the signals into motor or control intent; the intent is compiled into robot commands and delivered over a standard robot interface. BrainCo’s headline technical claim is that the full loop from thought to robot action completes in under 200 milliseconds. The graphical developer interface is designed so that an engineer with no prior brain-computer interface experience can go from unboxing to a live brain-controlled robot demonstration in what BrainCo describes as about ten minutes. That last claim is marketing, not benchmarked. It is worth attributing to BrainCo without echoing it as fact.

Three robot form factors were on the WAIC floor: a humanoid, a robotic arm, and a quadruped. The specific product SKUs were not disclosed in the English-language wire coverage, and Inside BCI is not naming them without a verified source. The platform’s positioning is that its Neuro-Embodied-AI stack sits on top of any of them, and that developers can wire their preferred robot into the toolkit without deep knowledge of the underlying brain-signal decoding.

Nyx He, whom BrainCo’s own press release identifies as partner and senior vice president, spoke the on-record framing at the launch: “A decade of BCI research has given us the ability to decode what a person intends to do and translate that into machine action. By integrating brain-computer interfaces, AI, and embodied AI, we believe it will define the next chapter of human-machine collaboration.” The reference to a decade is the eleven-year arc from BrainCo’s 2015 founding in Somerville, Massachusetts, where Han Bicheng incubated the company at Harvard Innovation Labs while a PhD candidate at Harvard’s Center for Brain Science, through the 2018 relocation of its legal and operational headquarters to Hangzhou, the BrainRobotics prosthetic hand line, the education-focused Focus EEG headband, and the medical bionic products also on display at the WAIC booth: the Revo 3 twenty-one-degree-of-freedom dexterous robotic hand, the 383-gram Intelligent Bionic Hand prosthetic, and the Intelligent Bionic Leg. BrainCo’s second WAIC product debut, the Embodied AI Data Collection Solution, pairs a dual-arm wheeled data-collection platform with a high-precision data glove and EEG capture from the human operator, aimed at the training-data bottleneck in humanoid robotics.

Where this sits in BrainCo’s commercial arc

The immediate strategic context for the WAIC launch is BrainCo’s Hong Kong Stock Exchange confidential IPO filing in January 2026, arranged by CICC and UBS Group, that Inside BCI covered in the 10 July 2026 CNBC BrainCo piece and again in the 22 June 2026 Neuracle STAR Market IPO piece. The Hong Kong track puts BrainCo in a direct race with Neuracle Technology (Shanghai) Co., Ltd., which had its STAR Market prospectus accepted on the Shanghai Stock Exchange on 11 June 2026 with CITIC Securities as sponsor. Neuracle reached a specific commercial milestone on 13 July 2026 that BrainCo has not: the first commercial implantation of a domestically approved invasive brain-computer interface medical device, at Shanghai Huashan Hospital, which Inside BCI covered on 16 July 2026. BrainCo’s WAIC launch is the non-invasive branch of the same Chinese commercial expansion. The two companies are competing for the informal title of Chinese brain-computer interface first-listed stock (脑机接口第一股), and they are pursuing it from opposite ends of the invasiveness spectrum. Neuracle from inside the skull with pneumatic-glove motor restoration for cervical spinal cord injury, BrainCo from outside the skull with a developer platform for controlling humanoid robots.

The BrainRobotics prosthetic hand is the specific product line that the WAIC platform ships alongside and that grounds BrainCo’s decade-of-work claim. BrainRobotics received FDA clearance in 2022 for its myoelectric-plus-neural-signal robotic hand, priced at a fraction of comparable US and European prosthetics, and has been the company’s main revenue-generating hardware product since. The WAIC platform is a departure from the single-product-single-patient model. It aims at the developer market rather than the end user. If BrainCo lands the platform commercially at the price point Chinese competitors are quoting for embodied-AI development kits, this becomes an SDK business rather than a hardware business, and the addressable market shifts from amputees and stroke patients to the roughly two hundred humanoid-robotics startups that Chinese state media count in the country’s current cohort.

What the “world’s first” claim excludes, precisely

The bare superlative in BrainCo’s press release does not survive fact-check for reasons Inside BCI is calling out here because a Tier 1 reader would find them in twenty minutes. The BrainGate consortium demonstrated brain-driven robotic arm control in Cathy Hutchinson’s 2012 Nature paper, in which she drank coffee unassisted using a robotic arm driven by an implanted Utah microelectrode array. Nathan Copeland at the University of Pittsburgh has controlled robotic arms with Utah Arrays since his 2015 implant, including the Modular Prosthetic Limb from Johns Hopkins Applied Physics Laboratory that added somatosensory feedback in 2016, coverage of which Inside BCI published yesterday. Noland Arbaugh, the first Neuralink N1 recipient, has publicly demonstrated robotic arm control with the implant during 2025 and 2026 events. The Feinstein Institutes’ “double neural bypass,” which Inside BCI covered in an adjacent piece today, drives Keith Thomas’s own paralysed hand rather than a robot but uses the same architecture: cortical intent, AI decoding, external actuator. On the non-invasive side, EMOTIV’s Cortex SDK, OpenBCI’s BrainFlow, and g.tec’s BCI System have offered commercial EEG-to-robot developer toolkits for over a decade; the MIT Media Lab drove a Boston Dynamics Spot quadruped from an EEG headband in 2024 and published the result peer-reviewed in Sensors.

What is genuinely new in BrainCo’s Friday launch is not the ability to control a robot with brain signals. It is the packaging of the toolkit for the Chinese humanoid-robotics developer pool, with a graphical no-code interface, three named third-party robot integrations out of the box, and BrainCo’s own Neuro-Embodied-AI framework compiling brain intent into AI action-planning steps before the robot command is delivered. That is a real product. Whether it is world-first depends on what part of it is being claimed as world-first, and neither BrainCo nor its wire republishers have specified precisely which layer of the stack the claim rests on. The most defensible narrower claim would be that the platform is China’s first commercially available brain-to-embodied-AI developer toolkit sold as an integrated research product. Even that would need verification against NeuroXess, StairMed, and NeuCyber launches in the same WAIC 2026 window, none of which have surfaced in the coverage so far.

What to watch

Watch which Chinese robotics companies buy the platform as an SDK integration partner. If any of the country’s humanoid, robotic-arm, or quadruped vendors move from being WAIC-floor demonstration partners to commercial licensees paying for BrainCo’s Neuro-Embodied-AI framework to ship inside their robot products, the developer-platform positioning proves out. If they stay at the demonstration-partner level and BrainCo’s revenue continues to come from BrainRobotics prosthetic hand sales, the WAIC launch was a PR moment rather than a business-model shift.

Watch the Neuracle STAR Market listing versus BrainCo Hong Kong Stock Exchange listing race through the second half of 2026. Neuracle’s prospectus was accepted on 11 June 2026; BrainCo’s confidential filing landed in January 2026 with CICC and UBS as arrangers. Neither has priced. Whichever prices first will hold the informal Chinese brain-computer interface first-listed-stock title, and the WAIC platform is BrainCo’s public-facing pre-IPO story.

Watch whether any of NeuroXess, StairMed, or NeuCyber unveils a competing brain-to-robot platform product at the remaining days of WAIC 2026 or in the immediate aftermath. Chinese state-industrial coordination on brain-computer interfaces is running at a specific policy tempo that Inside BCI has been tracking through the 4 July 2026 NMPA Announcement No. 24 coverage, the 26 June 2026 Guangdong Dual-Core Action Plan, the 7 July 2026 Beijing Changfazhan Future Industry designation, and the 10 July 2026 Xizang Lhasa first-plateau BCI centre inauguration. If BrainCo’s platform is the first of several competing Chinese brain-to-robot developer toolkits announced in the next quarter, the “world’s first” framing collapses into “one of several.” If BrainCo stays alone in the developer-platform lane through the end of 2026, the framing survives.

Watch the export-control side. A commercial Chinese brain-computer interface developer platform that ships with pipelines into humanoid robots is exactly the kind of dual-use technology the US Committee on Foreign Investment and the Department of Commerce Entity List have paid attention to. BrainCo has US operations and US customers on the BrainRobotics prosthetic side. Whether the WAIC platform draws regulatory attention on either side of the Pacific is a downstream commercial-policy signal worth tracking through the end of the year.

Sources

market BrainCo WAIC-2026 Shanghai brain-controlled-robot EEG Neuro-Embodied-AI Nyx-He Han-Bicheng Hangzhou-Six-Little-Dragons BrainRobotics HKEX-IPO Industrial-Builder-posture

What the platform actually is

Where this sits in BrainCo’s commercial arc

What the “world’s first” claim excludes, precisely

What to watch

Weekly BCI Brief in your inbox